NYSE:AET - Aetna Stock Price, Price Target & More

$176.09 -1.44 (-0.81 %)

(As of 04/19/2018 03:07 PM ET)

Previous Close$177.53

Today's Range$175.89 - $177.41

52-Week Range$128.79 - $194.40

Volume660,404 shs

Average Volume2.50 million shs

Market Capitalization$57.96 billion

P/E Ratio17.89

Dividend Yield1.13%

Beta0.67

About Aetna (NYSE:AET)

Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.

Receive AET News and Ratings via Email

Sign-up to receive the latest news and ratings for AET and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospital & medical service plans

Sub-IndustryManaged Health Care

SectorMedical

SymbolNYSE:AET

CUSIP00817Y10

Webwww.aetna.com

Phone860-273-0123

Debt

Debt-to-Equity Ratio0.52%

Current Ratio0.65%

Quick Ratio0.65%

Price-To-Earnings

Trailing P/E Ratio17.89

Forward P/E Ratio15.98

P/E Growth1.43

Sales & Book Value

Annual Sales$60.54 billion

Price / Sales0.95

Cash Flow$12.3572 per share

Price / Cash14.25

Book Value$48.46 per share

Price / Book3.63

Profitability

EPS (Most Recent Fiscal Year)$9.86

Net Income$1.90 billion

Net Margins3.15%

Return on Equity21.50%

Return on Assets5.87%

Miscellaneous

Employees47,950

Outstanding Shares326,940,000

How to Become a New Pot Stock Millionaire

Aetna (NYSE:AET) Frequently Asked Questions

What is Aetna's stock symbol?

Aetna trades on the New York Stock Exchange (NYSE) under the ticker symbol "AET."

How often does Aetna pay dividends? What is the dividend yield for Aetna?

Aetna declared a quarterly dividend on Friday, February 23rd. Shareholders of record on Thursday, April 12th will be paid a dividend of $0.50 per share on Friday, April 27th. This represents a $2.00 annualized dividend and a yield of 1.14%. The ex-dividend date is Wednesday, April 11th. View Aetna's Dividend History.

How will Aetna's stock buyback program work?

Aetna declared that its board has initiated a share buyback program on Friday, April 7th 2017, which permits the company to buyback $4,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 98% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's leadership believes its stock is undervalued.

How were Aetna's earnings last quarter?

Aetna (NYSE:AET) released its quarterly earnings data on Tuesday, January, 30th. The company reported $1.25 EPS for the quarter, beating the Zacks' consensus estimate of $1.18 by $0.07. The company had revenue of $14.74 billion for the quarter, compared to analyst estimates of $14.79 billion. Aetna had a return on equity of 21.50% and a net margin of 3.15%. The business's revenue was down 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.08 earnings per share. View Aetna's Earnings History.

When is Aetna's next earnings date?

Aetna is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Aetna.

What price target have analysts set for AET?

18 brokerages have issued twelve-month price objectives for Aetna's shares. Their predictions range from $158.00 to $212.00. On average, they expect Aetna's stock price to reach $189.8235 in the next twelve months. View Analyst Ratings for Aetna.

What are Wall Street analysts saying about Aetna stock?

Here are some recent quotes from research analysts about Aetna stock:

1. According to Zacks Investment Research, "Aetna’s third-quarter earnings surpassed the Zacks Consensus Estimate and grew year over year, driven by strong underwriting margin performance, disciplined pricing, a focus on high quality care management, and a decline in medical cost. Aetna’s shares have outperformed the industry year to date. We expect the company to witness long-term growth from its Government business and International expansion. Its cost-reduction initiatives will aid margins. The sale of its Group Life and Disability business will help it to focus on core growth areas. Following strong third-quarter results, Aetna raised its earnings guidance, cementing investors' confidence in it. Aetna has, however, been incurring losses in its public exchange business and has been exiting exchanges. Furthermore, its membership growth remains under pressure. Increasing medical benefit ratios are also likely to hurt margins." (11/2/2017)
2. Cantor Fitzgerald analysts commented, "There is life after Humana. CEO Mark Bertolini opened the meeting discussing life after Humana. With a continued focus to grow its government business, Mr. Bertolini indicated that Humana represented a means to an end." Instead, AET will now chose to build its government business organically. We believe the company will also pursue acquisitions to build out its capabilities in specific geographies. CFO Shawn Guertin identified Medicare as a great growth opportunity, but characterized Medicaid as a good opportunity. Growth in Medicaid slowed recently due to two contract losses and potential for structural changes to Medicaid exist." (5/12/2017)
3. Royal Bank of Canada analysts commented, "After the close on Monday, April 24, Humana pre-released 1Q17 EPS ahead of its investor meeting, which will be held on Tuesday, April 25. 1Q17 Adjusted EPS for the quarter was $2.75 vs. our estimate of $2.50 and FactSet consensus of $2.49." (4/24/2017)

Who are some of Aetna's key competitors?

Some companies that are related to Aetna include Medtronic (MDT), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), Gilead Sciences (GILD), AstraZeneca (AZN), Thermo Fisher Scientific (TMO), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), CSL (CSL), Celgene (CELG), GlaxoSmithKline (GSK), Becton Dickinson (BDX), Stryker (SYK), Anthem (ANTM), Allergan (AGN) and Biogen (BIIB).

Who are Aetna's key executives?

Aetna's management team includes the folowing people:

Mr. Mark Thomas Bertolini, Chairman & CEO (Age 61)
Ms. Karen Sue Lynch, Pres (Age 55)
Mr. Shawn Michael Guertin, Exec. VP, CFO & Chief Enterprise Risk Officer (Age 54)
Mr. Thomas J. Sabatino Jr., Exec. VP & Gen. Counsel (Age 59)
Ms. Margaret M. McCarthy, Exec. VP of Operations & Technology (Age 64)

Has Aetna been receiving favorable news coverage?

News headlines about AET stock have trended somewhat negative recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aetna earned a media sentiment score of -0.03 on Accern's scale. They also gave headlines about the company an impact score of 47.01 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Aetna?

Shares of AET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aetna's stock price today?

One share of AET stock can currently be purchased for approximately $176.09.

How big of a company is Aetna?

Aetna has a market capitalization of $57.96 billion and generates $60.54 billion in revenue each year. The company earns $1.90 billion in net income (profit) each year or $9.86 on an earnings per share basis. Aetna employs 47,950 workers across the globe.

How can I contact Aetna?

Aetna's mailing address is 151 FARMINGTON AVENUE, HARTFORD CT, 06156. The company can be reached via phone at 860-273-0123 or via email at [email protected]

MarketBeat Community Rating for Aetna (AET)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		708 (Vote Outperform)
Underperform Votes:		479 (Vote Underperform)
Total Votes:		1,187

MarketBeat's community ratings are surveys of what our community members think about Aetna and other stocks. Vote "Outperform" if you believe AET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AET will underperform the S&P 500 over the long term. You may vote once every thirty days.

Aetna (NYSE:AET) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Aetna in the last 12 months. Their average twelve-month price target is $189.8235, suggesting that the stock has a possible upside of 7.80%. The high price target for AET is $212.00 and the low price target for AET is $158.00. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.61	2.65	2.59	2.70
Ratings Breakdown:	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 9 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$189.8235	$189.8235	$174.8333	$163.4706
Price Target Upside:	7.80% upside	1.27% upside	3.24% downside	7.94% upside

Aetna (NYSE:AET) Consensus Price Target History

Price Target History for Aetna (NYSE:AET)

Aetna (NYSE:AET) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/31/2018	Jefferies Group	Reiterated Rating	Hold	$205.00	Low
1/31/2018	Credit Suisse Group	Boost Price Target	Neutral -> Neutral	$200.00 -> $208.00	Medium
1/31/2018	Citigroup	Downgrade	Buy -> Neutral	$187.89 -> $212.00	Low
1/30/2018	Cowen	Reiterated Rating	Buy	$212.00	Low
1/30/2018	Piper Jaffray	Reiterated Rating	Buy	$212.00	Low
1/22/2018	Deutsche Bank	Upgrade	Hold -> Buy	$195.00 -> $212.00	Low
12/20/2017	Morgan Stanley	Downgrade	Overweight -> Equal Weight	$179.00	Low
12/6/2017	Argus	Downgrade	Buy -> Hold	$185.00	Low
12/4/2017	Wells Fargo	Reiterated Rating	Outperform	$200.00 -> $208.00	High
11/3/2017	Raymond James	Upgrade	Market Perform -> Outperform	$200.00	N/A
10/27/2017	BMO Capital Markets	Boost Price Target	Market Perform	$175.00 -> $200.00	N/A
10/26/2017	Cantor Fitzgerald	Downgrade	Overweight -> Neutral		N/A
8/4/2017	Royal Bank of Canada	Boost Price Target	Outperform -> Outperform	$162.00 -> $171.00	Medium
5/17/2017	UBS	Reiterated Rating	Buy	$147.00 -> $160.00	N/A
5/17/2017	Bank of America	Reiterated Rating	Buy	$160.00 -> $168.00	Medium
5/16/2017	Stifel Nicolaus	Boost Price Target	Buy -> Buy	$150.00 -> $158.00	Low
5/15/2017	Barclays	Reiterated Rating	Overweight	$162.00	Low
5/11/2017	Cleveland Research	Upgrade	Neutral -> Buy		Low
4/3/2017	CIBC	Reiterated Rating	Outperform		Low
3/31/2017	Oppenheimer	Reiterated Rating	Outperform		Low
1/31/2017	Sanford C. Bernstein	Downgrade	Outperform -> Market Perform		N/A
1/24/2017	Leerink Swann	Downgrade	Outperform -> Market Perform	$135.00	N/A
9/22/2016	Evercore ISI	Initiated Coverage	Buy	$128.00	N/A
8/17/2016	FBR & Co	Reiterated Rating	Hold		N/A
7/21/2016	Wolfe Research	Downgrade	Outperform -> Peer Perform		N/A
5/16/2016	Sterne Agee CRT	Reiterated Rating	Buy		N/A

(Data available from 4/19/2016 forward)

Aetna (NYSE:AET) Earnings History and Estimates Chart

Earnings by Quarter for Aetna (NYSE:AET)

Aetna (NYSE:AET) Earnings Estimates

2018 EPS Consensus Estimate: $11.08
2019 EPS Consensus Estimate: $12.50

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$2.95	$3.18	$3.05
Q2 2018	3	$3.31	$3.47	$3.37
Q3 2018	3	$2.75	$3.07	$2.93
Q4 2018	3	$1.57	$1.95	$1.73
Q1 2019	1	$3.45	$3.45	$3.45
Q2 2019	1	$3.62	$3.62	$3.62
Q3 2019	1	$3.26	$3.26	$3.26
Q4 2019	1	$2.17	$2.17	$2.17

Aetna (NYSE AET) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018		$2.98					N/A
1/30/2018	Q4 2017	$1.18	$1.25	$14.7884 billion	$14.7420 billion	View	N/A
10/31/2017	Q3 2017	$2.06	$2.45	$15.1197 billion	$14.9940 billion	View	N/A
8/3/2017	Q2 2017	$2.34	$3.42	$15.3354 billion	$15.5230 billion	View	Listen
5/2/2017	Q1 2017	$2.36	$2.71	$15.3893 billion	$15.1650 billion	View	Listen
1/31/2017	Q416	$1.44	$1.63	$15.84 billion	$15.73 billion	View	Listen
10/27/2016	Q316	$2.02	$2.07	$15.71 billion	$15.78 billion	View	Listen
8/2/2016	Q216	$2.12	$2.21	$15.69 billion	$15.95 billion	View	Listen
4/28/2016	Q116	$2.23	$2.30	$15.46 billion	$15.69 billion	View	Listen
2/1/2016	Q415	$1.21	$1.37	$14.93 billion	$15.09 billion	View	Listen
10/29/2015	Q315	$1.77	$1.90	$15.22 billion	$15.00 billion	View	Listen
8/4/2015	Q215	$1.82	$2.05	$15.43 billion	$15.13 billion	View	Listen
4/28/2015	Q115	$1.96	$2.39	$15.48 billion	$15.09 billion	View	Listen
2/3/2015	Q414	$1.22	$1.22	$14.59 million	$14.77 million	View	Listen
10/28/2014	Q214	$1.58	$1.79	$14.63 billion	$14.70 billion	View	Listen
7/29/2014	Q114	$1.61	$1.69	$13.98 billion	$14.50 billion	View	Listen
4/24/2014	Q413	$1.56	$1.98	$13.69 billion	$13.97 billion	View	Listen
2/6/2014	Q313	$1.36	$1.34	$13.14 billion	$13.13 billion	View	Listen
10/29/2013	Q213	$1.53	$1.53	$12.89 billion	$12.99 billion	View	Listen
7/30/2013	Q2 2013	$1.39	$1.52	$12.02 billion	$11.56 billion	View	Listen
4/30/2013	Q1 2013	$1.38	$1.50	$9.65 billion	$9.51 billion	View	Listen
1/31/2013	Q4 2012	$0.96	$0.94	$8.97 billion	$8.96 billion	View	Listen
10/25/2012	Q312	$1.34	$1.55	$8.96 billion	$8.90 billion	View	N/A
7/31/2012		$1.25	$1.31			View	N/A
4/26/2012		$1.39	$1.34			View	N/A
2/1/2012		$0.96	$0.97			View	N/A
10/27/2011		$1.14	$1.40			View	N/A
7/27/2011		$1.07	$1.35			View	N/A
4/28/2011		$0.97	$1.43			View	N/A
2/4/2011		$0.62	$0.63			View	N/A
11/3/2010	Q3 2010	$0.67	$0.84			View	N/A
7/27/2010	Q2 2010	$0.73	$1.05			View	N/A
4/29/2010	Q1 2010	$0.72	$0.77			View	N/A
2/5/2010	Q4 2009	$0.42	$0.40			View	N/A
10/29/2009	Q3 2009	$0.66	$0.69			View	N/A
7/27/2009	Q2 2009	$0.79	$0.69			View	N/A
4/29/2009	Q1 2009	$0.93	$0.96			View	N/A
2/12/2009	Q4 2008	$0.95	$0.96			View	N/A
10/29/2008	Q3 2008	$1.12	$1.12			View	N/A
7/31/2008	Q2 2008	$0.93	$0.94			View	N/A
4/24/2008	Q1 2008	$0.92	$0.92			View	N/A
2/7/2008	Q4 2007	$0.88	$0.88			View	N/A

(Earnings results data provided by Zacks Investment Research)

Aetna (NYSE:AET) Dividend Information

Aetna pays an annual dividend of $2.00 per share, with a dividend yield of 1.14%. AET's next quarterly dividend payment will be made on Friday, April 27. Aetna pays out 20.28% of its earnings out as a dividend.

Next Dividend:	4/27/2018
Annual Dividend:	$2.00
Dividend Yield:	1.14%
Dividend Growth:	24.80% (3 Year Average)
Payout Ratio:	20.28% (Trailing 12 Months of Earnings) 18.15% (Based on This Year's Estimates) 16.38% (Based on Next Year's Estimates)
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Aetna (NYSE:AET)

Aetna (NYSE:AET) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/23/2018	quarterly	$0.50	1.13726828158763%	4/11/2018	4/12/2018	4/27/2018
12/4/2017	quarterly	$0.50	1.12%	1/10/2018	1/11/2018	1/26/2018
9/29/2017	quarterly	$0.50	1.25%	10/11/2017	10/12/2017	10/27/2017
5/19/2017	quarterly	$0.50	1.42%	7/11/2017	7/13/2017	7/28/2017
2/17/2017	quarterly	$0.50	1.58%	4/11/2017	4/13/2017	4/28/2017
12/2/2016	quarterly	$0.25	0.77%	1/10/2017	1/12/2017	1/27/2017
9/30/2016	quarterly	$0.25	0.87%	10/11/2016	10/13/2016	10/28/2016
5/20/2016	quarterly	$0.25	0.91%	7/12/2016	7/14/2016	7/29/2016
2/19/2016	quarterly	$0.25	0.94%	4/12/2016	4/14/2016	4/29/2016
12/4/2015	quarterly	$0.25	0.97%	1/12/2016	1/14/2016	1/29/2016
9/25/2015	quarterly	$0.25	0.95%	10/13/2015	10/15/2015	10/30/2015
5/15/2015	quarterly	$0.25	0.88%	7/14/2015	7/16/2015	7/31/2015
2/27/2015	quarterly	$0.25	1%	4/7/2015	4/9/2015	4/24/2015
11/21/2014	quarterly	$0.25	1.15%	1/13/2015	1/15/2015	1/30/2015
9/19/2014	quarterly	$0.2250	1.08%	10/14/2014	10/16/2014	10/31/2014
5/30/2014	quarterly	$0.2250	1.16%	7/8/2014	7/10/2014	7/25/2014
2/28/2014	quarterly	$0.2250	1.25%	4/8/2014	4/10/2014	4/25/2014
12/6/2013	quarterly	$0.2250	1.35%	1/14/2014	1/16/2014	1/31/2014
9/27/2013	quarterly	$0.20	1.25%	10/8/2013	10/10/2013	10/25/2013
5/17/2013	quarterly	$0.20	1.35%	7/9/2013	6/11/2013	7/26/2013
2/19/2013	quarterly	$0.20	1.66%	4/9/2013	4/11/2013	4/26/2013

(Data available from 1/1/2013 forward)

Aetna (NYSE AET) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.21%
Institutional Ownership Percentage: 87.28%

Insider Trading History for Aetna (NYSE:AET)

Aetna (NYSE AET) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2017	Karen S Lynch	President	Sell	15,271	$161.91	$2,472,527.61	64,261
9/15/2017	Margaret M Mccarthy	EVP	Sell	10,288	$162.85	$1,675,400.80	33,563
6/7/2017	Margaret M Mccarthy	EVP	Sell	27,028	$149.23	$4,033,388.44	33,563
5/17/2017	Mark T Bertolini	Chairman	Sell	103,547	$140.79	$14,578,382.13	659,888
3/23/2017	Shawn M Guertin	Insider	Sell	29,602	$129.35	$3,829,018.70	44,880
3/8/2017	Francis S Soistman Jr	VP	Sell	6,607	$131.98	$871,991.86	23,454
9/7/2016	Jeffrey E. Garten	Director	Sell	7,100	$116.51	$827,221.00
8/23/2016	Shawn M Guertin	Insider	Sell	45,328	$120.21	$5,448,878.88	44,883
5/10/2016	Margaret M Mccarthy	EVP	Sell	39,169	$114.45	$4,482,892.05	56,240
5/3/2016	Mark T Bertolini	CEO	Sell	33,510	$114.00	$3,820,140.00	496,588
3/15/2016	Gary W Loveman	EVP	Buy	8,970	$111.45	$999,706.50	9,605
2/22/2016	Molly Joel Coye	Director	Sell	1,175	$106.28	$124,879.00	8,104
12/23/2015	Margaret M Mccarthy	EVP	Sell	18,373	$109.97	$2,020,478.81	63,515
12/22/2015	Mark T. Bertolini	CEO	Sell	26,996	$110.00	$2,969,560.00	729,194
8/14/2015	Joseph M Zubretsky	EVP	Sell	179,087	$118.66	$21,250,463.42
8/13/2015	Franklin Barbara Hackman	Director	Sell	2,064	$118.47	$244,522.08
3/31/2015	Joseph M Zubretsky	EVP	Sell	200,000	$107.96	$21,592,000.00
3/27/2015	Joseph M Zubretsky	EVP	Sell	86,958	$107.24	$9,325,375.92
3/26/2015	Joseph M Zubretsky	Insider	Sell	162,066	$106.98	$17,337,820.68
3/26/2015	Margaret M Mccarthy	EVP	Sell	27,670	$106.04	$2,934,126.80
3/25/2015	Franklin Barbara Hackman	Director	Sell	3,000	$108.75	$326,250.00
3/17/2015	William James Casazza	VP	Sell	14,000	$105.07	$1,470,980.00
3/2/2015	Molly Joel Coye	Director	Sell	2,500	$100.27	$250,675.00
2/10/2015	Rajan Parmeswar	VP	Sell	5,300	$95.60	$506,680.00
6/16/2014	Molly Joel Coye	Director	Sell	1,650	$80.60	$132,990.00
6/12/2014	William James Casazza	VP	Sell	15,906	$80.58	$1,281,705.48
5/27/2014	Franklin Barbara Hackman	Director	Sell	2,665	$77.26	$205,897.90
2/19/2014	Rajan Parmeswar	VP	Sell	3,600	$69.46	$250,056.00	3,829
12/30/2013	Mark Bertolini	CEO	Sell	130,272	$68.08	$8,868,917.76	526,938
12/27/2013	William James Casazza	VP	Sell	10,299	$68.25	$702,906.75	33,903
8/26/2013	William James Casazza	VP	Sell	15,745	$64.66	$1,018,071.70	33,903
6/18/2013	William James Casazza	VP	Sell	40,598	$62.00	$2,517,076.00
5/21/2013	Molly Joel Coye	Director	Sell	2,000	$60.38	$120,760.00
5/20/2013	Joseph P Newhouse	Director	Sell	14,000	$59.15	$828,100.00
5/15/2013	Rajan Parmeswar	VP	Sell	1,435	$60.13	$86,286.55
2/6/2013	Karen Rohan	VP	Buy	4,035	$49.53	$199,853.55

(Data available from 1/1/2013 forward)

Aetna (NYSE AET) News Headlines

Source:

Date	Headline
	What Are The Next Big Dividend Stocks? finance.yahoo.com - April 18 at 5:28 PM
	BRIEF-Aetna To Release Q1 2018 Results; Announces Business Segment Realignment www.reuters.com - April 17 at 5:40 PM
	Aetna to Release First-Quarter 2018 Results; Announces Business Segment Realignment finance.yahoo.com - April 17 at 5:39 PM
	Here's What to Watch as UnitedHealth Reports Earnings on Tuesday finance.yahoo.com - April 16 at 5:38 PM
	Analysts’ Recommendations for UnitedHealth Group finance.yahoo.com - April 16 at 9:09 AM
	Aetna to Post Q1 2018 Earnings of $3.01 Per Share, Jefferies Group Forecasts (AET) www.americanbankingnews.com - April 16 at 1:50 AM
	Aetna (AET) Downgraded by BidaskClub to Hold www.americanbankingnews.com - April 15 at 12:36 AM
	Prescription drug costs: Insurers look to pass price breaks straight to the consumer www.usatoday.com - April 14 at 5:35 PM
	Aetna Inc (AET) Forecasted to Earn Q3 2018 Earnings of $3.07 Per Share www.americanbankingnews.com - April 13 at 8:55 AM
	$15.20 Billion in Sales Expected for Aetna Inc (AET) This Quarter www.americanbankingnews.com - April 13 at 4:04 AM
	Shady Grove Fertility Atlanta Invited into Aetna's Institute of Excellence ™ Infertility Network www.benzinga.com - April 12 at 5:35 PM
	Aetna (AET) Stock Rating Reaffirmed by Cantor Fitzgerald www.americanbankingnews.com - April 12 at 2:19 PM
	Stock Traders Buy Large Volume of Aetna Put Options (AET) www.americanbankingnews.com - April 12 at 7:01 AM
	Aetna Inc (AET) Expected to Post Earnings of $3.01 Per Share www.americanbankingnews.com - April 11 at 9:19 AM
	Aetna Inc. (AET) Ex-Dividend Date Scheduled for April 11, 2018 www.nasdaq.com - April 10 at 5:31 PM
	Aetna About To Put More Money In Your Pocket (AET) www.nasdaq.com - April 9 at 5:35 PM
	Aetna (AET) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - April 8 at 10:51 AM
	Aetna (AET) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 7 at 9:13 AM
	BRIEF-Aetna Says Chairman And CEO Mark Bertolini's FY 2017 Total Compensation Was $18.8 Mln www.reuters.com - April 6 at 5:33 PM
	Blue Cross Blue Shield Insurers may be afoul of antitrust law seekingalpha.com - April 6 at 5:33 PM
	Aetna (AET) Downgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - April 5 at 7:58 PM
	Aetna (AET) Stock Rating Lowered by Cantor Fitzgerald www.americanbankingnews.com - April 4 at 6:22 PM
	Are Options Traders Betting on a Big Move in Aetna (AET) Stock? finance.yahoo.com - April 3 at 5:30 PM
	Aetna and Harvard T.H. Chan School of Public Health Launch Five-Year Well-Being Research Initiative finance.yahoo.com - April 3 at 5:30 PM
	Are Options Traders Betting on a Big Move in Aetna (AET) Stock? April 03, 2018 www.zacks.com - April 3 at 8:12 AM
	Aetna (AET) PT Raised to $185.00 at Jefferies Group www.americanbankingnews.com - April 2 at 12:26 PM
	Citigroup Increases Aetna (AET) Price Target to $197.00 www.americanbankingnews.com - April 2 at 12:30 AM
	Aetna Inc (AET) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - April 1 at 1:36 AM
	Aetna (AET) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - March 31 at 3:48 PM
	Aetna (AET) Rating Increased to Overweight at Piper Jaffray www.americanbankingnews.com - March 31 at 12:12 AM
	M&A News: Walmart in Talks to Buy Health Insurer Humana finance.yahoo.com - March 30 at 5:36 PM
	Walmart in early talks to buy insurer Humana, report says www.usatoday.com - March 30 at 8:27 AM
	Aetna Drug Rehab Resource Developed From Heroin Detox Clinics globenewswire.com - March 30 at 8:27 AM
	Aetna will pass drug rebates along to portion of members www.marketwatch.com - March 28 at 8:00 AM
	CEO named to lead Allina-Aetna's health-insurance joint venture www.bizjournals.com - March 27 at 5:32 PM
	Aetna Will Pass Along Discounts as Drug Price Scrutiny Increases www.bloomberg.com - March 27 at 5:32 PM
	Tom Lindquist Tapped as CEO of Allina Health Aetna Joint Venture finance.yahoo.com - March 27 at 5:32 PM
	CEO named to lead Allina-Aetna's health-insurance joint venture finance.yahoo.com - March 27 at 5:32 PM
	Aetna will pass drug discounts along to some members at the pharmacy counter finance.yahoo.com - March 27 at 5:32 PM
	Aetna (AET) Upgraded to Buy at Deutsche Bank www.americanbankingnews.com - March 27 at 10:26 AM
	Aetna to pass on drug rebates to some its members www.cnbc.com - March 27 at 9:30 AM
	Brokerages Anticipate Aetna Inc (AET) Will Post Quarterly Sales of $15.20 Billion www.americanbankingnews.com - March 27 at 4:59 AM
	Piper Jaffray Reiterates Buy Rating for Aetna (AET) www.americanbankingnews.com - March 26 at 1:26 PM
	Cowen Reaffirms Buy Rating for Aetna (AET) www.americanbankingnews.com - March 26 at 1:26 PM
	Aetna (AET) Rating Lowered to Neutral at Citigroup www.americanbankingnews.com - March 26 at 11:38 AM
	Why Aetna Inc Stock Will Rebound Soon investorplace.com - March 26 at 10:30 AM
	Aetna Rankings On Healthy Communities www.msn.com - March 26 at 8:59 AM
	U.S. News and Aetna Foundation Release Inaugural Healthiest Communities Rankings www.prnewswire.com - March 26 at 1:54 AM
	Aetna (AET) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 25 at 9:16 PM
	Internationally Recognized Addiction Expert Educates Panel at Aetna Forum to Combat Opioid Epidemic www.prnewswire.com - March 23 at 12:22 PM